RS2 Cost-Effectiveness of End-of-Life, Life-Extending Interventions: NICE's Cost-Effectiveness Threshold Explored
نویسندگان
چکیده
منابع مشابه
Five-hundred life-saving interventions and their cost-effectiveness.
We gathered information on the cost-effectiveness of life-saving interventions in the United States from publicly available economic analyses. "Life-saving interventions" were defined as any behavioral and/or technological strategy that reduces the probability of premature death among a specified target population. We defined cost-effectiveness as the net resource costs of an intervention per y...
متن کاملCost-Effectiveness Analysis of Health Interventions: A Critical Review
Background and Aim: Economic evaluation of health interventions by comparing the relevant costs and benefits will result in optimum allocation of resources and increasing the effectiveness of the health system and, through improving equity and increasing accessibility to health services, will lead to increased effectiveness of the health system. The purpose of this study was to critically evalu...
متن کاملCost-effectiveness of coronary interventions.
As the costs of medical care continue to rise, there has been increasing interest in evaluating the cost-effectiveness of medical practices. One area that has received particular scrutiny in recent years is percutaneous coronary revascularisation (PTCA). In the United States alone, more than 300 000 PTCAs are performed each year at an estimated cost of approximately US$3 billion. Despite the tr...
متن کامل[Cost-effectiveness of interventions for end-stage renal disease].
OBJECTIVE The study reports the cost-effectiveness results of end-stage renal disease (ESDR) patients in Mexico in terms of years of life gained and quality of life and the economic cost with regards to three treatment alternatives that could be considered mutually exclusive: continuous peritoneal ambulatory dialysis (CAPD), hemodialysis (HD) and renal transplant (RT). METHOD The economic cos...
متن کاملCost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant.
Unless they maintain Medicare status through disability or age, kidney transplant recipients lose their Medicare coverage of immunosuppression 3 years after transplantation. A significant transplant survival advantage has previously been demonstrated by the extension of Medicare immunosuppressive medication coverage from 1 year to 3 years, which occurred between 1993 and 1995. The United States...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2011
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.08.070